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Background: Nutritional support is crucial to the management of patients receiving invasive mechanical ventilation (IMV)
and the most commonly prescribed treatment in intensive care units (ICUs). International guidelines consistently indicate
that enteral nutrition (EN) should be preferred over parenteral nutrition (PN) whenever possible and started as early as
possible. However, no adequately designed study has evaluated whether a specific nutritional modality is associated with
decreased mortality. The primary goal of this trial is to assess the hypothesis that early first-line EN, as compared to early
first-line PN, decreases day 28 all-cause mortality in patients receiving IMV and vasoactive drugs for shock.
Methods/Design: The NUTRIREA-2 study is a multicenter, open-label, parallel-group, randomized controlled trial comparing
early PN versus early EN in critically ill patients requiring IMV for an expected duration of at least 48 hours, combined
with vasoactive drugs, for shock. Patients will be allocated at random to first-line PN for at least 72 hours or to
first-line EN. In both groups, nutritional support will be started within 24 hours after IMV initiation. Calorie targets
will be 20 to 25 kcal/kg/day during the first week, then 25 to 30 kcal/kg/day thereafter. Patients receiving PN
may be switched to EN after at least 72 hours in the event of shock resolution (no vasoactive drugs for 24 consecutive
hours and arterial lactic acid level below 2 mmol/L). On day 7, all patients receiving PN and having no contraindications
to EN will be switched to EN. In both groups, supplemental PN may be added to EN after day 7 in patients with persistent
intolerance to EN and inadequate calorie intake. We plan to recruit 2,854 patients at 44 participating ICUs.
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Discussion: The NUTRIREA-2 study is the first large randomized controlled trial designed to assess the hypothesis that
early EN improves survival compared to early PN in ICU patients. Enrollment started on 22 March 2013 and is expected to
end in November 2015.
Trial registration: ClinicalTrials.gov Identifier: NCT01802099 (registered 27 February 2013)
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Nutritional support is a key component of the life-
sustaining strategies used on an everyday basis in in-
tensive care units (ICUs) to combat the adverse effects
of critical illnesses. The latest international guidelines
recommend enteral nutrition (EN) as opposed to paren-
teral nutrition (PN) as the first-line route for nutritional
support [1-4]. EN has documented beneficial effects on
gastrointestinal mucosa integrity, wound healing, immune
function and response to tissue damage [5-7]. EN may
contribute to diminishing nosocomial infection rates,
length of stay and health-care costs [8-11]. Early EN
initiation (within 24 to 48 hours after ICU admission)
may enhance these beneficial effects and decrease mortal-
ity rates [12-15]. EN initiation within 48 hours after inva-
sive mechanical ventilation (IMV) has been reported to
improve outcomes of patients with multiple organ failure
[12,14]. Despite this evidence base, substantial gaps persist
between everyday practice and clinical guidelines about
nutritional support. EN is frequently delayed and PN used
in patients who are eligible for EN [16-18]. At least two
factors may explain the current underuse of EN—namely,
legitimate or exaggerated concerns about complications
related to EN and the absence of sound scientific evidence
that one route is superior to the other [19].
The most common complication of early EN is upper
gastrointestinal intolerance, which occurs in 30% to 70%
of ICU patients [20]. Upper gastrointestinal intolerance
manifests as gastric hypokinesia responsible for an in-
crease in the residual gastric volume, which in turn is
believed to increase the risk of gastroesophageal reflux,
aspiration and nosocomial pneumonia [21-28]. The se-
quence of incomplete gastric emptying, gastroesophageal
reflux, aspiration and nosocomial pneumonia is a constant
source of concern for health-care workers. Ventilator-
associated pneumonia (VAP) is a major complication
of IMV; it is seen in 8% to 27% of patients and is re-
sponsible for longer ICU stays and increased mortality
in some patients [29]. The measure most commonly
used to prevent or decrease the risk of upper gastro-
intestinal intolerance is discontinuation or substantial
reduction of the enteral feed flow rate. However, this
measure decreases energy and nutrient intake below
what is required to meet the needs of the patient. Anegative energy balance is associated with undernutrition,
which in turn correlates with higher rates of infection and
death in the most severely ill patients [30-35]. Concern
about VAP and undernutrition related to EN intolerance
is a major deterrent to the use of early EN [36-45]. EN has
also been associated with an increased risk of gut ischemia
in critically ill patients with shock [46-49]. Gut ischemia
may result in necrotizing enterocolitis, which is fatal in
70% to 100% of cases [50,51]. Factors involved in gut is-
chemia include impaired splanchnic blood flow, vasoactive
drug use, preexistent arterial disease and specific clinical
conditions such as renal failure, heart surgery, multiple
trauma, acute respiratory distress syndrome, septic shock,
cardiogenic shock and fluid overload [49,52,53]. Whether
EN contributes to the development of gut ischemia re-
mains controversial. Experimental studies have demon-
strated better preservation of gastrointestinal mucosal
integrity with EN [54,55]. However, splanchnic blood
flow has been found to increase by 50% with EN and
decrease by over 60% with PN, suggesting a risk of in-
adequate splanchnic oxygen supply in the face of high
demand in patients with shock who are receiving EN
[46]. Guidelines recommend postponing EN in patients
with shock until full resuscitation with achievement of
hemodynamic stability [2,3]. This delay in EN delivery
may be associated with calorie deficiencies and adverse
outcomes in patients with severe critical illnesses [30,34].
These considerations explain why clinicians perceive PN
as the safest means of delivering adequate energy and pro-
tein to patients at high risk for intolerance to EN or gut
ischemia.
Another contributor to the current underuse of early
EN in ICU patients may be the reliance of international
guidelines on studies that have provided low-level evi-
dence and on meta-analyses whose results are conflict-
ing [1,13,15]. Most meta-analyses comparing EN and PN
have shown no effect on mortality, but have indicated
that EN, compared to PN, was associated with decreases
in nosocomial infections, hospital and ICU lengths of
stay and health-care costs [9,10,56-58]. A meta-analysis
confined to trials involving an intention-to-treat analysis
(9 of 465 trials) demonstrated higher mortality with EN
than with PN [59]. However, all the available meta-
analyses included highly heterogeneous studies that were
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surgical patients and/or on patients who did not require
ventilatory support or who had critical illnesses of lim-
ited severity. These characteristics preclude drawing
definitive conclusions about the respective effects of
EN and PN in critically ill patients. Many authors have
emphasized the need for well-designed, adequately pow-
ered, randomized trials in uniform populations of ICU pa-
tients with severe critical illnesses associated with a high
risk of death and/or complications, in whom optimal nu-
tritional support raises the greatest challenges but is likely
to have the greatest impact on patient outcomes [59-61].
Study rationale
Patients with shock requiring both IMV and vasoactive
drugs are at high risk for complications and death. Given
their vulnerability to EN intolerance and gut ischemia,
guidelines indicate that EN should be postponed until
hemodynamic stability is restored [2,3]. These patients
consequently receive either delayed EN or initial PN, al-
though they may have a high likelihood of survival bene-
fits from early EN compared to PN, according to several
observational [12,14,17]. No adequately designed study
has compared early EN to early PN in this population.
The primary goal of the present trial is to assess the hy-
pothesis that early first-line EN decreases day 28 all-cause
mortality in these patients compared to early first-line PN.
Methods/Design
Design and setting
NUTRIREA-2 is a multicenter, open-label, parallel-group
randomized controlled trial in patients receiving IMV and
vasoactive drugs for shock. They will be allocated to early
first-line EN or early first-line PN in the acute phase of
ICU management.
Ethical aspects
The study protocol and patient information documents were
approved by the ethics committee of the French Society for
Intensive Care Medicine (Société de Réanimation de Langue
Française (SRLF) approval CE SRLF 11-340) and by the
competent French authorities (Comité de Protection des
Personnes de Poitiers registration 2011-A01483-38 (ap-
proved on 26 January 2012)). According to French law, as
the strategies used in both study arms are classified as
standard care, patient consent is not required; however,
the patients or their next of kin must be informed about
the study before enrollment. Before study enrollment, all
patients or their next of kin will confirm in writing that
they have received this information.
Participating units
Of the 44 French ICUs participating in the study, 28 are in
university hospitals. All participating ICU staff membershave received training in the study procedures and proto-
cols for providing nutritional support and managing EN
intolerance.
Study population
Eligible patients are adults (≥18 years of age) admitted
to the study ICUs who are expected to require IMV for
longer than 48 hours, are being treated with a vasoactive
drug (adrenaline, dobutamine or noradrenaline) via a cen-
tral venous catheter and are eligible for nutritional support
started within 24 hours after endotracheal intubation
(or within 24 hours after ICU admission if intubation
occurred before ICU admission).
Exclusion criteria are IMV started more than
24 hours after endotracheal intubation or ICU
admission; surgery on the gastrointestinal tract within
the past month; history of gastrectomy, esophagec-
tomy, duodenopancreatectomy, bypass surgery, gastric
banding or short bowel syndrome; gastrostomy or jeju-
nostomy; specific nutritional needs, such as preexisting
long-term home-based EN or PN; active gastrointestinal
bleeding; treatment limitation decisions; adult under
guardianship; pregnancy; breastfeeding; current inclusion
in a randomized trial designed to compare EN and PN;
and/or contraindication to PN (known hypersensitivity
to egg or soybean proteins or to another component,
inborn error in amino acid metabolism or severe famil-
ial dyslipidemia affecting triglyceride levels).
All patients receiving IMV and vasoactive drugs for
shock within 24 hours after ICU admission are screened
for eligibility by the ICU physicians and clinical research
nurses, around the clock and 7 days per week.
Randomization
Consecutive eligible patients are randomly allocated
in a 1:1 ratio to one of the two treatment groups: the
EN group or the PN group. Randomization is strati-
fied by centers. The patients are enrolled in each ICU
by the local physicians and a clinical research nurse
and/or clinical research assistant. Randomization and
concealment are ensured by using a secure, computer-
generated, interactive, response system available at each
study center and managed by the biometrical unit of the
Tours University Hospital, which has no role in
recruitment.
Study interventions
The study protocol and randomization arms are detailed
in Figure 1.
Parenteral nutrition group
In the PN group, the patients receive first-line PN for at
least 72 hours. The route used subsequently depends on
the results of the daily hemodynamic evaluations. If the
Figure 1 Study protocol. D, Day; EN, Enteral nutrition; ICU, Intensive care unit; PN, Parenteral nutrition.
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for 24 consecutive hours and arterial lactic acid level
below 2 mmol/L) and the enteral route can be used, PN
is stopped and immediately replaced by EN at the flow
rate needed to achieve the previously defined calorie tar-
get. If, on the contrary, the patient still requires vaso-
active drugs and/or the arterial lactic acid level is equal
to or greater than 2 mmol/L, PN is continued for a total
of 7 days (168 hours). On day 8, in the absence of contra-
indications to EN, PN is stopped and EN started, regard-
less of hemodynamic status. Supplemental PN may be
added in the event of persistent intolerance to EN pre-
cluding achievement of the predefined calorie target.
Enteral nutrition group
In the EN group, the patients receive first-line EN. In
the event of persistent gastrointestinal intolerance pre-
cluding achievement of the predefined calorie targets,
supplemental PN may be added starting on day 8 [3,62].
Isosmotic, isocaloric, normal protein polymeric prepara-
tions are used during the first week, after which thechoice of the preparation is at the discretion of the phys-
ician at the bedside. To minimize the risk of upper
gastrointestinal intolerance and consequently of vomit-
ing, the volume of supplemental water given via the gas-
tric route is as small as possible during the first study
week.
Nutritional support protocol
The nutritional support protocol, including measures
designed to evaluate tolerance, is standardized as indi-
cated below.
General principles of nutritional support in both study arms
Nutritional support is started as soon as possible after
IMV initiation and no later than 24 hours after intubation
or after ICU admission in patients intubated before ICU
admission. The calorie target for each patient is estimated
based on body weight as 20 to 25 kcal/kg/day during the
acute phase (day 0 to day 7), then 25–30 kcal/kg/day from
day 8 to extubation. The recommended calorie target is
20 kcal/kg/day during the acute phase (day 0 to day 7)
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tients (body mass index (BMI) greater than 30 kg/m2), the
body weight yielding a BMI of 30 kg/m2 is used to esti-
mate the calorie target.
Nutritional support is prescribed as a flow rate (in mil-
liliters per hour) and started at the flow rate required to
achieve the calorie target on day 1 (as opposed to a grad-
ual increase). The feed is delivered continuously over the
24-hour cycle without interruption. Actual feed delivery is
monitored regularly by comparing delivered volumes to
predefined daily calorie targets. In addition, special atten-
tion is directed to avoiding delays. Any interruption in
feed delivery is reported to the ICU physician in charge.
Usually, nutritional support is not interrupted while trans-
porting the patient. However, when EN or PN must be
interrupted (for example, for a specific gastrointestinal or
radiological investigation), the flow rate is not increased to
compensate for the interruption. All patients are kept in
the semirecumbent supine position.
After extubation, regardless of time since randomization,
decisions about the continued need for, and optimal route
of, nutritional support are made by the physician in charge
of the patient. Patients who are reintubated within 7 days
after trial inclusion are managed until the end of the acute
phase according to the arm to which they were random-
ized during the first period of intubation. Patients reintu-
bated after the end of the acute phase (day 7) receive EN in
the absence of contraindications.
Enteral nutrition
The feed is delivered continuously via a 14-French sili-
cone gastric tube. The tube’s position in the middle of
the stomach is checked on a radiograph obtained at ICUFigure 2 Protocol for managing upper gastrointestinal intolerance.
is correct.admission or immediately after tube placement, as well
as when the tube is changed or repositioned. Special at-
tention is directed to the risk of tube obstruction, par-
ticularly when administering medications. The tube is
flushed regularly with 20 to 30 ml of water.
A predefined protocol is used to manage upper gastro-
intestinal intolerance to EN (Figure 2). Residual gastric
volume is not monitored [63]. EN tolerance is assessed
based only on episodes of significant vomiting or regur-
gitation (passage of feed into the mouth, outside the
mouth or into the endotracheal tube in the absence of
care procedures or mobilization). Minimal regurgitation
or vomiting triggered by tracheal aspiration or oral cav-
ity care is not taken to indicate intolerance. EN intoler-
ance (that is, significant vomiting or regurgitation) leads
to the following two measures. First, treatment with a
prokinetic agent is to be administered after confirmation
that there are no contraindications. The study ICUs use
the prokinetic agent of their choice according to their
standard practice. The prokinetic agent is continued
until EN at the highest prescribed flow rate has been
well tolerated for 48 hours. The prokinetic agent is then
discontinued. Second, if gastric intolerance persists des-
pite prokinetic therapy, the flow rate is decreased by
25 ml/hr every 6 hours until the signs of intolerance re-
solve. Therefore, EN is stopped (and the gastric tube
placed under suction) only in patients with intolerance
despite a flow rate ≤25 ml/hr. All interruptions in EN
delivery must be reported to the physician in charge of
the patient. EN is resumed at the prescribed flow rate
(appropriate to the patient’s needs) after 6 hours have
elapsed without further signs of intolerance. Patients at
high risk for gastric intolerance, such as those turned inGI, Gastrointestinal; NGT, Nasogastric tube. Response J Reignier: this
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receive prophylactic prokinetic treatment starting at the
first turn in the prone position [64,65].
Parenteral nutrition
Ternary admixtures packaged in bags and containing the
three groups of macronutrients are used according to
standard practice in each participating center. Supple-
mental electrolytes are provided in a solution separate
from the parenteral feed, according to the needs of each
patient. PN is delivered continuously via a central ven-
ous catheter (CVC). Special attention is directed to prevent-
ing infections by complying with the standard protocols for
CVC insertion and maintenance followed in each of the par-
ticipating centers. Proper CVC position is checked routinely
on a radiograph.
Additional intakes
Additional water and electrolytes are given intravenously
according to the needs of each patient as assessed by the
physician in charge and in compliance with standard
practice in each study ICU. Intravenous vitamins and
trace elements are given according to the needs of each
individual patient using the standard preparations and
protocols available in each study ICU. These compo-
nents are not added to the PN bags. Instead, they are
given continuously over the 24-hour cycle using a separ-
ate intravenous bag and line; if needed, this separate
preparation is shielded from light using aluminum foil.
Intestinal transit monitoring
Stool volume and appearance are monitored daily. Constipa-
tion (no stool for more than 6 days) or diarrhea (more than
300 ml of liquid stool or more than four loose stools per
day) must be reported. Episodes of diarrhea are managedFigure 3 Protocol for diarrhea management.according to a specific diagnostic and therapeutic protocol
(Figure 3) [66].
Diagnosis of ventilator-associated pneumonia
VAP is suspected in patients with new and persistent or
progressive lung infiltrates on the chest radiograph, com-
bined with at least two of the following criteria: body
temperature ≥38.5°C or ≤35.5°C, peripheral leukocytosis
(>10,000/mm3) or leukopenia (<4,000/mm3), and purulent
tracheal aspirates. The diagnosis must be confirmed in
each participating ICU on the basis of a positive semi-
quantitative bacteriological result from a distal respiratory
specimen: bronchoalveolar lavage fluid (positive if there
are ≥104 colony-forming units (cfu)/ml), protected speci-
men brush (positive if there are ≥103 cfu/ml) or tracheo-
bronchial aspirate (positive if there are ≥105 cfu/ml)
[29,67]. VAP episodes are recorded from 48 hours after
intubation until day 2 after extubation.
Diagnosis of bowel ischemia
Bowel ischemia is defined in this trial as absent blood
flow in one of the main arteries supplying the bowel (su-
perior mesenteric artery, inferior mesenteric artery or
celiac artery) with evidence of bowel wall compromise
on an imaging study (computed tomography angiog-
raphy, angiography or magnetic resonance angiography)
or the presence of rectosigmoidoscopy- or colonoscopy-
based criteria for colonic ischemia according to the
Favier classification system (stage I, petechiae; stage II,
petechiae and superficial ulcers; and stage III, necrotic
ulcers and polypoid lesions) [68].
Data collection and follow-up
At the time of inclusion, the following baseline charac-
teristics are recorded: age, sex, date of ICU admission,
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score, Knaus score and preexisting comorbidities (includ-
ing chronic renal failure, liver failure, pulmonary disease
and heart failure; malignant disease; and immunosuppres-
sion). Use of sedatives, insulin, proton pump inhibitors,
dialysis, neuromuscular blockers and gastric prokinetic
agents before inclusion are also recorded. The Simplified
Acute Physiology Score II is computed 24 hours after ICU
admission [69].
The information listed below is recorded daily until
extubation or until day 28 during intubation, whichever
occurs first.
1. Nutritional data: name of the enteral or parenteral
preparation, target volume and number of calories,
volume and calories delivered per day, vomiting
(yes/no, daily), decrease or discontinuation of
nutritional support (yes/no), reason for decreasing
or discontinuing nutritional support (vomiting,
diarrhea, acute colonic pseudo-obstruction, other
acute abdominal symptoms, abdominal complication,
imaging study, other), stools (yes/no, daily) and diarrhea
with its presumed cause (intolerance to nutritional
support, medication, Clostridium difficile, other).
2. Treatments: prokinetic agent, sedation,
neuromuscular blockers, catecholamines (dobutamine,
noradrenaline or adrenaline), renal replacement
therapy, antibiotics, insulin (total dose/24 hr), volume
of intravenous fluids (total/24 hr) and gastric
antisecretory agents (sucralfate, proton pump
inhibitors, histamine receptor antagonists, other).
3. Laboratory data: (a) at baseline—hemoglobin,
leukocytes, platelets, Na+, K+, Ca2+, pH,
triglycerides, partial pressure of oxygen in arterial
blood (PaO2), partial pressure of carbon dioxide in
arterial blood, pH, arterial lactic acid, bicarbonate,
urea, creatinine, bilirubin, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), γ-glutamyl
transpeptidase, alkaline phosphatase and total
protein; (b) daily from day 1 to day 7 or until
extubation—PaO2, arterial lactic acid, bilirubin,
AST, ALT, γ-glutamyl transpeptidase, alkaline
phosphatase, glucose, protein, Na+, K+, Ca2+, pH,
triglycerides and creatinine; (c) on day 1 and on
day 7 or the day of extubation—albumin, prealbumin
and C-reactive protein levels; daily from day 1 to day
7—Sepsis-related Organ Failure Assessment (SOFA)
score [70].
4. Nosocomial infections (one data collection form per
infection): VAP (date of diagnosis, organism, resistance
profile), bacteremia (date of diagnosis, organism,
resistance profile), intravascular catheter-related
infection (date of diagnosis, organism, resistance
profile), urinary tract infection (date of diagnosis,organism, resistance profile), soft tissue infection
(date of diagnosis, organism, resistance profile) and
other (type, date of diagnosis, organism, resistance
profile).
5. Invasive devices: endotracheal tube, intravascular
catheters and urinary catheters, with the dates of
insertion and removal for each.
6. Each patient is followed until hospital discharge or
day 90, whichever occurs first. Vital status is
recorded at ICU discharge, at hospital discharge, on
day 28 and on day 90. Table 1 is the study flowchart.
Organization of the trial
Funding/support
NUTRIREA-2 is sponsored by the La Roche sur Yon
Hospital (Centre Hospitalier de la Vendée, La Roche sur
Yon, France) and supported by a grant from the French
Ministry of Health (Programme Hospitalier de Recherche
Clinique 2012, PHRC-12-0184).
Coordination and conduct of the trial
Before the start of patient recruitment procedures, all
physicians and other health-care workers in the 44 par-
ticipating ICUs attended formal training sessions on the
study protocol and data collection in the electronic case
report form (eCRF). All documents required for the
study are available in each ICU. The eCRF is a secure,
interactive, web response system available at each study
center, provided and managed by the biometrical unit of
the Tours University Hospital (CIC INSERM 1415, Tours,
France). In each participating ICU, the physicians and a
clinical research nurse and/or clinical research assistant
are in charge of daily patient screening and inclusion, en-
suring compliance with the study protocol and collecting
the study data in the eCRFs. The Clinical Research Unit of
the La Roche-sur-Yon Hospital will review the screening
forms and clinical data at regular intervals. The principal
investigators will meet with the ICU teams to discuss any
problems with data collection and protocol compliance
and to evaluate study progress. According to French law,
the eCRF and database organization have been approved
by the appropriate committees (CCTIRS: Comité Consul-
tatif sur le Traitement de l’Information en matière de
Recherche dans le domaine de la Santé; and CNIL: Com-
mission Nationale de l’Informatique et des Libertés).
Interim analyses
Given the need for a large sample size, two interim ana-
lyses are scheduled, one after enrollment of 1,000 pa-
tients and the other after enrollment of 2,000 patients.
The independent Data Safety Monitoring Board (DSMB)
is composed of two physicians and one biostatistician
not otherwise involved in the trial. For both interim ana-
lyses, the DSMB will have access to unblinded results on
Table 1 Study flowchart
Inclusion Day 0a Day 1 to Day n End of study Day 28 Day 90
Eligibility: check inclusion and exclusion criteria X





Laboratory tests X X
SOFA scoreb X X
Nutritional evaluation X X
Treatments used X X
Daily calorie intake X
Nosocomial infections X
Final extubation X
Final discontinuation of nutritional support X
Survived/died X X X
aFrom time at inclusion to 11:59 PM. bSOFA, Sepsis-related Organ Failure Assessment.
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to day 7, blood bilirubin values and nosocomial infec-
tions. The results of the interim analyses will not be dis-
closed unless they lead the DSMB to request premature
trial discontinuation.
Blinding
Blinding of the physicians, nurses and patients to the
use of EN and/or PN is not feasible. The absence of
blinding cannot have an impact, however, because the
primary outcome is objective (day 28 mortality) [71].
Moreover, all VAP diagnoses are adjudicated by an inde-
pendent blinded committee on the basis of all available
clinical, radiological and bacteriological data.
Study outcomes
Primary endpoint
The primary endpoint is all-cause mortality by day 28.
Information on this endpoint is collected on the 28th
day after patient inclusion in the study. For discharged
patients, information on the primary endpoint is col-
lected by a telephone call to the patient at home.
Secondary endpoints
The following are the secondary endpoints of the study:
1. The proportion of patients with at least one VAP
episode
2. VAP incidence density per 1,000 days of IMV (that
is, ratio of the number of patients with at least one
VAP episode during IMV or within 2 days after
extubation over the period at risk, defined asfollows: total number of IMV days in patients
without VAP or number of IMV days before the first
VAP episode in patients with VAP)
3. Number of VAP episodes per patient
4. Proportion of patients with at least one episode of
bacteremia and incidence density of bacteremia per
1,000 ICU days
5. Proportion of patients with at least one CVC-related
infection and incidence density of CVC-related
infections per 1,000 CVC days
6. Proportion of patients with at least one episode of
urinary tract infection and incidence density of
urinary tract infections per 1,000 urinary catheter days
7. Proportion of patients with at least one soft tissue
infection and incidence density of soft tissue
infections per 1,000 ICU days
8. Proportion of patients with other nosocomial
infections and incidence density of other nosocomial
infections per 1,000 ICU days
9. Proportion of patients with at least one nosocomial
infection
10. Descriptive bacteriological data (organisms
recovered in the overall population of nosocomial
infections and antimicrobial resistance profiles)
11. Proportion of patients with at least one episode of
vomiting or regurgitation during IMV
12. Proportion of patients with at least one episode of
diarrhea
13. Proportion of patients with at least one
documented episode of bowel ischemia
14. Number of calories (in kilocalories) delivered
enterally and parenterally (daily mean during the
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IMV)
15. Ratio (as a percentage) of prescribed over delivered
calories via the enteral and parenteral routes (daily
mean during the first week, daily mean throughout
the time on IMV and proportion of patients who
achieved their calorie target on each follow-up day)
16. Volume of liquid feed (in milliliters) delivered
(daily mean during the first week and daily mean
throughout the time on IMV)
17. Variations in SOFA scores from day 1 to day 7
18. ICU mortality, 90-day mortality and hospital
mortality
19. Mean changes in serum albumin, prealbumin and
C-reactive protein measured at baseline, at the
end of IMV, on day 7 (in patients on IMV for
more than 7 days) and at ICU discharge
20. Proportion of patients with at least one
liver dysfunction episode (defined as serum
bilirubin >50 μmol/L and/or γ-glutamyl transferase,
alkaline phosphatase and/or AST or ALT >3 N)
evaluated at the end of IMV, on day 7 (in patients
on IMV for more than 7 days) and at ICU discharge
21. ICU length of stay
22. Hospital length of stay
23. Time on IMV
24. Changes in mean body weight determined at
baseline, on day 7 and at ICU discharge
Sample size
The working hypothesis of this randomized controlled
trial is that day 28 all-cause mortality in patients admit-
ted to the ICU and treated with IMV and vasoactive
drugs will be lower when early nutritional support is
provided enterally rather than parenterally. We have de-
termined that 1,427 patients are needed in each group
(2,854 patients in all), assuming a 37% day 28 mortality
rate in the PN group and a 5% decrease in mortality with
early EN (that is, a 32% day 28 mortality rate), with a
4.9% two-sided type I error rate and 80% power, given
that two interim analyses will be performed, and given
that the statistical tests will be performed using signifi-
cance thresholds of 0.001 for the two interim analyses
and 0.049 for the final analysis according to the Peto’s
method [72]. The mortality rates used for the sample
size estimation are those obtained in the NUTRIREA-1
randomized controlled trial performed in nine centers
using similar inclusion criteria [63].
Statistical analysis
The statistical analysis will follow the intention-to-treat ap-
proach; that is, each patient will remain in the group
assigned by randomization, regardless of subsequent events.
A statistical analysis report will be written to describe all thefindings according to CONSORT statement recommenda-
tions, taking into account the specific features of the trial,
most notably the nonpharmacological nature of the inter-
vention (Figure 4). The baseline features of the groups estab-
lished by randomization will be compared using descriptive
statistics. No statistical tests will be performed.Primary endpoint
Day 28 mortality will be reported as the point estimates
with the 95% confidence intervals in each group and
compared between the two groups using the χ2 test.Secondary endpoints
The analysis of patients with at least one nosocomial in-
fection will rely on the competing-risk concept with
death as the competing risk, because patients who have
died cannot experience nosocomial infections. For the
proportion of patients with at least one VAP episode, the
method used will be the same as that used for nosoco-
mial infections, with not only death as a competing risk
but also time to extubation +2 days, because, after this
point, any episode of pneumonia would not be classified
as a VAP episode. The number of VAP episodes per
patient will be analyzed using a negative binomial re-
gression model with no offset variable. Bacteremia, CVC-
related infections, urinary tract infections and soft tissue
infections will be analyzed using the same method as that
used for the pooled nosocomial infections. For descriptive
bacteriological data (organisms recovered with their resist-
ance profiles for each nosocomial infection), only descrip-
tive analyses will be performed. For the proportion of
patients with at least one episode of vomiting or regur-
gitation, diarrhea, constipation, documented acute colonic
pseudo-obstruction (Ogilvie syndrome), documented bowel
ischemia, mechanical complication of CVC insertion and
liver dysfunction, the method used will be the same as that
employed for the nosocomial infections. Changes over time
in calories delivered daily by the enteral and parenteral
routes and changes over time in enteral and parenteral feed
volumes delivered daily will be compared between the two
groups using a mixed linear model, after data transform-
ation if necessary. The proportions of patients who
achieved their daily calorie target will be compared between
the two groups using a logistic random-effects model. Day
90 mortality will be analyzed in the same way as day 28
mortality. For ICU and hospital mortality rates, competing-
risk models will be used, as ICU discharge and hospital dis-
charge compete with death during the stay. Changes over
time in nutritional markers and body weight will be ana-
lyzed using the method described above for the number of
calories delivered. ICU length of stay, hospital length of stay
and IMV duration will be compared between the two
groups using nonparametric Wilcoxon tests.
Figure 4 Flow diagram of NUTRIREA-2 trial according to CONSORT.
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Nutritional support, whether delivered enterally or par-
enterally, is among the first-line treatments used rou-
tinely in the ICU. Guidelines state that the enteral route
should be preferred to the parenteral route and should
be used early in the course of the critical illness. How-
ever, guidelines are poorly followed and are not sup-
ported by adequately designed clinical studies. To date,
no study has produced definitive information on the
risks and benefits of EN versus PN in critical care.
NUTRIREA-2 is the first large randomized controlled
trial designed to evaluate the hypothesis that early EN
decreases mortality compared to PN in ICU patients.
The NUTRIREA-2 sample size provides sufficient statis-
tical power to detect a significant mortality rate decrease
on day 28. The study focuses on patients receiving IMV
and vasoactive drugs for shock, because such very se-
verely ill ICU patients with multiple organ failure may
be most likely to benefit from early EN compared to
early PN. Furthermore, at present, many of these pa-
tients do not receive early nutritional support or early
PN, despite being eligible for EN. However, thesepatients are considered at high risk for complications
of EN, such as upper gastrointestinal intolerance, VAP
or bowel ischemia. If the study hypothesis is con-
firmed, early EN will become the reference standard
for initial nutritional support in patients with shock
who are receiving IMV, and this change will decrease
morbidity and mortality rates and improve patient
outcomes.
Trial status
Enrollment is ongoing. Inclusion started in March 2013.
By 10 March 2014, 1,000 patients had been included.
The first interim analysis was performed on these 1,000
patients and led the DSMB to recommend continuation
of the study. By 15 December 2014, 1,795 patients had
been included. Recruitment is expected to be complete
by November 2015.
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